Version 1
: Received: 7 June 2023 / Approved: 7 June 2023 / Online: 7 June 2023 (10:47:26 CEST)
How to cite:
Mostallino, R.; Santoni, M.; Sagheddu, C.; Serra, V.; Orrù, V.; Pistis, M.; Castelli, M.P. The PPARα Agonist Fenofibrate Reduces the Levels of Proinflammatory Cytokines in a Maternal Immune Activation Model of Schizophrenia. Preprints2023, 2023060539. https://doi.org/10.20944/preprints202306.0539.v1
Mostallino, R.; Santoni, M.; Sagheddu, C.; Serra, V.; Orrù, V.; Pistis, M.; Castelli, M.P. The PPARα Agonist Fenofibrate Reduces the Levels of Proinflammatory Cytokines in a Maternal Immune Activation Model of Schizophrenia. Preprints 2023, 2023060539. https://doi.org/10.20944/preprints202306.0539.v1
Mostallino, R.; Santoni, M.; Sagheddu, C.; Serra, V.; Orrù, V.; Pistis, M.; Castelli, M.P. The PPARα Agonist Fenofibrate Reduces the Levels of Proinflammatory Cytokines in a Maternal Immune Activation Model of Schizophrenia. Preprints2023, 2023060539. https://doi.org/10.20944/preprints202306.0539.v1
APA Style
Mostallino, R., Santoni, M., Sagheddu, C., Serra, V., Orrù, V., Pistis, M., & Castelli, M.P. (2023). The PPARα Agonist Fenofibrate Reduces the Levels of Proinflammatory Cytokines in a Maternal Immune Activation Model of Schizophrenia. Preprints. https://doi.org/10.20944/preprints202306.0539.v1
Chicago/Turabian Style
Mostallino, R., Marco Pistis and M. Paola Castelli. 2023 "The PPARα Agonist Fenofibrate Reduces the Levels of Proinflammatory Cytokines in a Maternal Immune Activation Model of Schizophrenia" Preprints. https://doi.org/10.20944/preprints202306.0539.v1
Abstract
Maternal infections during pregnancy may increase the risk of psychiatric disorders in offspring. We recently demonstrated that activation of peroxisome proliferator-activate receptor‐α (PPARα), with the clinically available agonist fenofibrate, attenuates the neurodevelopmental disturbances induced by maternal immune activation (MIA) in rat offspring. We hypothesized that fenofibrate might reduce MIA-induced cytokine imbalance using a MIA model based on the viral mimetic polyriboinosinic-polyribocytidilic acid [poly (I:C)]. By using the Bio-Plex Multiplex-Immunoassay-System, we measured cytokine/chemokine levels in maternal serum and in the fetal brain of rats treated with fenofibrate, at 6 and 24 hours after poly (I:C). We found that MIA induced time-dependent changes in the levels of several cytokines/chemokines/colony-stimulating factors (CSFs). Specifically, the maternal serum of the poly (I:C)/CTRL group showed increased levels of (i) proinflammatory chemokine macrophage inflammatory protein 1-alpha (MIP-1α), (ii) tumor necrosis factor-alpha (TNF-), the monocyte chemoattractant protein-1 (MCP-1), the macrophage (M-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF). Conversely, in the fetal brain of the poly (I:C)/CTRL group, interleukin 12p70 and MIP-1 levels were lower than in veh/CTRL group. Notably, MIP-1, TNF-, GRO/KC, GM-CSF, and M-CSF levels were lower in the poly (I:C)/FEN than in poly (I:C)/CTRL rats, indicating the protective role of the PPARα agonist. PPARα might represent a therapeutic target to attenuate the consequences of MIA.
Biology and Life Sciences, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
